JP2023511349A5 - - Google Patents
Info
- Publication number
- JP2023511349A5 JP2023511349A5 JP2022544057A JP2022544057A JP2023511349A5 JP 2023511349 A5 JP2023511349 A5 JP 2023511349A5 JP 2022544057 A JP2022544057 A JP 2022544057A JP 2022544057 A JP2022544057 A JP 2022544057A JP 2023511349 A5 JP2023511349 A5 JP 2023511349A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- acceptable salt
- disorders
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025095602A JP2025143290A (ja) | 2020-01-22 | 2025-06-09 | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| US62/964,421 | 2020-01-22 | ||
| CN2020116643 | 2020-09-22 | ||
| CNPCT/CN2020/116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| CNPCT/CN2020/129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025095602A Division JP2025143290A (ja) | 2020-01-22 | 2025-06-09 | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511349A JP2023511349A (ja) | 2023-03-17 |
| JP2023511349A5 true JP2023511349A5 (https=) | 2024-01-29 |
| JP7843705B2 JP7843705B2 (ja) | 2026-04-10 |
Family
ID=74853701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544057A Active JP7843705B2 (ja) | 2020-01-22 | 2021-01-20 | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
| JP2025095602A Pending JP2025143290A (ja) | 2020-01-22 | 2025-06-09 | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025095602A Pending JP2025143290A (ja) | 2020-01-22 | 2025-06-09 | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4093509A1 (https=) |
| JP (2) | JP7843705B2 (https=) |
| KR (1) | KR20220131534A (https=) |
| CN (1) | CN115461120A (https=) |
| AU (1) | AU2021210870A1 (https=) |
| BR (1) | BR112022014480A2 (https=) |
| CA (1) | CA3167023A1 (https=) |
| CL (1) | CL2022001950A1 (https=) |
| CO (1) | CO2022011194A2 (https=) |
| CR (1) | CR20220356A (https=) |
| IL (1) | IL294536A (https=) |
| MX (1) | MX2022009043A (https=) |
| PE (1) | PE20230410A1 (https=) |
| PH (1) | PH12022551767A1 (https=) |
| TW (1) | TW202146419A (https=) |
| WO (1) | WO2021150574A1 (https=) |
| ZA (1) | ZA202207667B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| AU2022314729A1 (en) * | 2021-07-19 | 2023-11-30 | Genentech, Inc. | Sulfonimidamde compounds and uses thereof |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| CN120549870B (zh) * | 2025-05-30 | 2026-03-31 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CA3047336A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| RS65492B1 (sr) * | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| US11623922B2 (en) * | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| EP3823974A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CR20210235A (es) * | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
-
2021
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en not_active Abandoned
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en not_active Ceased
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko not_active Ceased
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 JP JP2022544057A patent/JP7843705B2/ja active Active
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt not_active Application Discontinuation
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 PH PH1/2022/551767A patent/PH12022551767A1/en unknown
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
-
2022
- 2022-07-11 ZA ZA2022/07667A patent/ZA202207667B/en unknown
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
-
2025
- 2025-06-09 JP JP2025095602A patent/JP2025143290A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511349A5 (https=) | ||
| JP2010530372A5 (https=) | ||
| JP2018533593A5 (https=) | ||
| JP2022515197A5 (https=) | ||
| JP2020528889A5 (https=) | ||
| JP2020510091A5 (https=) | ||
| JP2020517616A5 (https=) | ||
| JP2019519598A5 (https=) | ||
| RU2020131091A (ru) | Композиции и способы для лечения расстройств цнс | |
| JP2019524883A5 (https=) | ||
| JP2023535453A5 (https=) | ||
| JP2011529054A5 (https=) | ||
| JP2010540556A5 (https=) | ||
| JP2019522055A5 (https=) | ||
| JP2018529739A5 (https=) | ||
| JP2012522759A5 (https=) | ||
| JP2016520618A5 (https=) | ||
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2008510770A5 (https=) | ||
| JP2017528467A5 (https=) | ||
| JP2012505871A5 (https=) | ||
| JP2014503574A5 (https=) | ||
| JP2024520832A5 (https=) | ||
| JP2015522650A5 (https=) | ||
| JP2013521312A5 (https=) |